Noopept dosage

Protocol

1. 1

   Measure the dose

   Typical Noopept dose is 20 mg (Russian clinical range 10 to 30 mg/day, typically split into 2 to 3 doses). Use a weight-based calculator for individual adjustments.

   Open tool →
2. 2

   Set the frequency

   Administer 2 to 3 times daily, last dose before mid-afternoon. Half-life of 0.7 hours anchors the dosing interval.

   Open tool →
3. 3

   Cycle if needed

   Russian protocols typically run 4 to 8 week blocks with 2 to 4 week washouts; long-term continuous use is not formally studied

   Open tool →
4. 4

   Monitor for side effects

   Watch for: headache; irritability; sleep disturbance with late-day dosing; occasional blood pressure elevation. Stop or reduce dose if tolerability breaks down.

Why this dose

Hydrolyzed to active metabolite cycloprolylglycine; AMPA receptor modulation, BDNF and NGF upregulation, antioxidant and antiexcitotoxic effects.

The typical dose (20 mg) reflects Russian clinical range 10 to 30 mg/day, typically split into 2 to 3 doses. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Noopept is administered via the oral or sublingual routes. Oral dosing is straightforward: take with water, with or without food unless specifically noted. Sublingual dosing requires holding the dose under the tongue for 60 to 90 seconds before swallowing to maximize mucosal absorption.

Onset of action runs around 30 minutes after administration. Peak effect lands near 1 hour post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Parent compound 30 to 50 minutes; cycloprolylglycine metabolite several hours

Cycling and tolerance

Russian protocols typically run 4 to 8 week blocks with 2 to 4 week washouts; long-term continuous use is not formally studied

Effects to expect at typical dose

• Russian dipeptide nootropic developed in the 1990s, registered in Russia 2002 for cognitive impairment
• Roughly 1,000-fold higher per-mg potency than piracetam; therapeutic dose 10 to 30 mg/day
• Active metabolite cycloprolylglycine modulates AMPA receptors and increases NGF and BDNF in rodent hippocampus
• Russian RCTs in stroke recovery and vascular cognitive impairment show modest improvements over 4 to 8 weeks
• Western evidence base is essentially absent; healthy-adult enhancement trials have not been published
• Unscheduled in the US but not approved for human consumption; UK is prescription-only since 2014

Side effects and interactions

Common side effects

• headache
• irritability
• sleep disturbance with late-day dosing
• occasional blood pressure elevation

Notable interactions

• memantine and other glutamatergic agents (minor): theoretical AMPA-pathway interaction
• antidepressants (minor): theoretical effect via BDNF axis, undocumented
• antihypertensives (minor): occasional blood pressure elevation may require monitoring

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Noopept profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

unknown

DEA / Rx

Not scheduled in the US

Pregnancy

Not recommended

Legal status

Approved in Russia and CIS states; prescription-only in UK; unscheduled and unapproved in US, EU varies

Do not use if

• pregnancy
• lactation
• pediatric use
• severe hepatic impairment
• severe renal impairment

Related research